Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment

• Paul Mitchell ,

  * E-mail: paul.mitchell@sydney.edu.au

  Affiliation Department of Ophthalmology and Westmead Millennium Institute, University of Sydney, Westmead, New South Wales, Australia

  ⨯
• Neil Bressler,

  Affiliation Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Quan V. Doan,

  Affiliation Outcomes Insights, Inc., Westlake Village, California, United States of America

  ⨯
• Chantal Dolan,

  Affiliation CMD Consulting, Inc., Sandy, Utah, United States of America

  ⨯
• Alberto Ferreira,

  Affiliation Novartis, Basel, Switzerland

  ⨯
• Aaron Osborne,

  Current address: Alcon Research Ltd., Fort Worth, Texas, United States of America

  Affiliation Novartis, Basel, Switzerland

  ⨯
• Elena Rochtchina,

  Affiliation Department of Ophthalmology and Westmead Millennium Institute, University of Sydney, Westmead, New South Wales, Australia

  ⨯
• Mark Danese,

  Affiliation Outcomes Insights, Inc., Westlake Village, California, United States of America

  ⨯
• Shoshana Colman,

  Affiliation Genentech, Inc., South San Francisco, California, United States of America

  ⨯
• Tien Y. Wong

  Affiliations Singapore Eye Research Institute, National University of Singapore, Singapore, Singapore, Centre for Eye Research Australia, University of Melbourne, Parkville, Victoria, Australia

  ⨯